Figure 4
Patients who demonstrated molecular relapse in advance of clinical relapse. Each panel shows VAF for patient-specific tumor markers across various timepoints. Clinical relapse is denoted with a vertical dotted line. Low-performing probes (< 1,000X observed coverage) were not shown. (A) NTN021 showed no signal at baseline or at C1D3. A spike in patient-specific VAFs occurred at 24 months, which was 7 months prior to clinical relapse. (B) NTN028 showed evidence of patient-specific VAFs at baseline with an increase in VAF at C1D3. The VAF of patient-specific markers were undetectable from 3 months until 12 months with a spike in VAF at 18 months, which was 3 months prior to clinical relapse. (C) NTN033 showed patient-specific VAFs at baseline and at C1D3. Patient-specific markers were undetectable at time of surgery and at 6 months. Patient-specific markers spiked at 12 months, which was 5 months prior to clinical relapse. (D) NTN076 showed non-zero VAFs of patient-specific markers at the time of surgery with clinical relapse 2 months post-operation.
